Research analysts at StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Get Rating) in a research note issued to investors on Monday. The brokerage set a “hold” rating on the stock.
Brooklyn ImmunoTherapeutics Stock Up 0.0 %
Shares of NYSE:BTX opened at $0.21 on Monday. The business’s fifty day simple moving average is $2.97. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10. The firm has a market capitalization of $12.07 million, a PE ratio of -0.09 and a beta of 4.61.
Hedge Funds Weigh In On Brooklyn ImmunoTherapeutics
A hedge fund recently bought a new stake in Brooklyn ImmunoTherapeutics stock. Lake Street Advisors Group LLC purchased a new position in shares of Brooklyn ImmunoTherapeutics Inc (NYSE:BTX – Get Rating) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 2,446,417 shares of the company’s stock, valued at approximately $604,000. Lake Street Advisors Group LLC owned about 4.16% of Brooklyn ImmunoTherapeutics as of its most recent SEC filing. 26.00% of the stock is owned by institutional investors.
Brooklyn ImmunoTherapeutics Company Profile
Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.
Further Reading
- Get a free copy of the StockNews.com research report on Brooklyn ImmunoTherapeutics (BTX)
- MarketBeat Week in Review – 5/29 – 6/2
- Trading Channel Breakout in Lululemon Brought by Earnings
- What Should Investors Make of These 3 Dividend Cuts?
- Constellation Brands Taps into Growth: Analysts Bullish on Stock
- CrowdStrike: Another Tech Stock to Buy on the Dip
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
